1. |
Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry, 2004, 75(8): 1135-1140.
|
2. |
Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med, 2018, 378(9): 840-1851.
|
3. |
Gong X, Chen C, Liu X, et al. Long-term functional outcomes and relapse of anti-nmda receptor encephalitis: a cohort study in western China. Neurol Neuroimmunol Neuroinflamm, 2021, 8(2): e985.
|
4. |
Yang J, Liu X. Immunotherapy for refractory autoimmune encephalitis. Frontiers in Immunology, 2021, 12: 790962.
|
5. |
Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology, 2016, 15(4): 391-404.
|
6. |
Graus F, Vogrig A, Muniz CS, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm, 2021, 8(4): e1014.
|
7. |
Spatola M, Sabater L, Planagumà J, et al. Encephalitis with mGluR5 antibodies Symptoms and antibody effects. Neurology, 2018, 90(22): e1964-1972.
|
8. |
Spatola M, Petit-Pedrol M, Simabukuro, MM, et al. Investigations in GABA(A) receptor antibody-associated encephalitis. Neurology, 2017, 88(11): 1012-1020.
|
9. |
Rosenfeld MR, Dalmau J. Paraneoplastic syndromes of the nervous system. Cancer neurology in clinical practice. Book: Mayo Clinic Family Health Book, 5th Edition, 2008.
|
10. |
Saiz A, Bruna J, Stourac P, et al. Anti-Hu-associated brainstem encephalitis. J Neurol Neurosurg Psychiatry, 2009, 80(4): 404-407.
|
11. |
Pittock SJ, Parisi JE, McKeon A, et al. Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Archives of Neurology, 2010, 67(9): 1109-1115.
|
12. |
Mandel C, Dubey D, Kryzer TJ, et al. Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis. New England Journal of Medicine, 2019, 381(1): 47-54.
|
13. |
Irani S, Pettingill P, Kleopa K, et al. Morvan syndrome: clinical and serological observations in 29 cases. Annals of neurology, 2012, 72(2): 241-255.
|
14. |
Flanagan E, Mckeon A, Lennon V, et al. Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology, 2011, 76(24): 2089-2095.
|
15. |
Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology, 2008, 71(24): 1955-1958.
|
16. |
Dubey D, Lennon VA, Gadoth A, et al. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology, 2018, 90(2): e103-e110.
|
17. |
Dubey D, Jitprapaikulsan J, Bi H, et al. Amphiphysin-IgG autoimmune neuropathy: A recognizable clinicopathologic syndrome. Neurology, 2019, 93(20): e1873-e1880.
|
18. |
Jitprapaikulsan J, Klein CJ, Pittock SJ, et al. Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG. J Neurol Neurosurg Psychiatry, 2020, 91(3): 328-330.
|
19. |
Jeffery O, Lennon V, Pittock S, et al. GABAB receptor autoantibody frequency in service serologic evaluation. Neurology, 2013, 81(10): 882-887.
|
20. |
Joubert B, Kerschen P, Zekeridou A, et al. Clinical spectrum of encephalitis associated with antibodies against the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor: case series and review of the literature. JAMA neurology, 2015, 72(10): 1163-1169.
|
21. |
Titulaer M, Mccraken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. The Lancet Neurology, 2013, 12(2): 157-165.
|
22. |
Honorat J, Didelot A, Karantoni E, et al. Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology, 2013, 80(24): 2226-2232.
|
23. |
Cai MT, Qiao S, Lai QL, et al. Evaluation of the updated diagnostic criteria for paraneoplastic neurologic syndromes in China. Front Immunol, 2022, 13: 790400.
|